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Summary Several unique features of neuroblastoma (NB), including the capacity for spontaneous regression and maturation to benign
pathology, suggest that genes that regulate cellular proliferation, survival and differentiation may be involved in directing clinical tumour
aggressiveness. The in situ expression of Bcl-2, Rb, p21, p53 and Bax proteins, as well as the proliferation marker proliferating cell nuclear
antigen (PCNA) were examined immunocytochemically in a selection of 38 stage- and outcome-identified NB tumours. Apoptotic cells were
identified morphologically and by a DNA fragmentation labelling technique (TUNEL). Although the tumour cell density of Bcl-2, p53, Bax,
PCNA and TUNEL positivity correlated with patient survival, a spatially organized expression pattern was further recognized in stroma-poor
differentiating tumours. Immature tumour cells adjacent to thin fibrovascular stroma are proliferating, as evidenced by PCNA positivity, and
often express Bcl-2. At increasing distance from this fibrovascular stroma, intermediately differentiated tumour cells express Rb, while with
more advanced differentiation, proliferation ceases and Bcl-2 immunoreactivity is lost. The most differentiated tumour cells, which often
express p53, and occasionally p21 and Bax, lie adjacent to TUNEL-positive, morphologically apoptotic cells. This spatial organization in
favourable outcome NB tumours suggests that physiological regulation of differentiation and apoptosis may be involved in tumour regression.
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Neuroblastoma (NB) is an embryonal malignancy of infancy and
childhood that may originate at any site at which sympathetic
nervous system (SNS) tissue is located. The prognosis of patients
with NB is highly dependent upon patient age at diagnosis and
clinical tumour stage; younger patients with lesser tumour burden
enjoying the most favourable prognosis (Evans et al, 1971;
Shimada etal, 1984). Several unique features ofNB suggestthatthe
molecular events controlling cellular proliferation, growth arrest,
differentiation and particularly cellular death may be involved in
dictating clinical aggressiveness. For instance: (1) spontaneous
regression of a predominantly infantile subgroup of highly meta-
static tumours, referred to as IVS, occurs more frequently in NB
than in any other tumour (D'Angio et al, 1971; Evans et al, 1976a;
Everson and Cole, 1966); (2) NB in situ, the finding ofneuroblastic
tumours in adrenal glands obtained from non-afflicted infants at
autopsy, indicates a high incidence of unrecognized spontaneous
resolution (Beckwith and Martin, 1968; Beckwith and Perrin,
1962); (3) advanced morphological tumour cell differentiation
correlates with favourable patient outcome (Shimada et al, 1984);
and (4) spontaneous tumourmaturation ofmalignant NB tumours to
that ofbenign pathology, i.e. ganglioneuroma, is recognized (Evans
et al, 1976b; Nitschke et al, 1988). Ourprevious work suggests that
the extent of apoptosis and proliferation, and the phenotypic mode
of tumour cellular differentiation, may be helpful in explaining
tumour biology (Gestblom et al, 1995; Hedborg et al, 1995a;
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Hoehner et al, 1995a, b). These characteristics lead us to hypothe-
size that the disparity in clinical behaviour ofdifferent forms ofNB
mayinvolve differences intheregulationofapoptosis-related genes.
Several genes that dictate cellular decisions regarding prolifera-
tion, growth arrest and cellular death have been identified. p53 is a
tumour-suppressor gene (Dowell and Hall, 1994), the protein
product of which normally suppresses tumour formation by
promoting the transcription of genes that inhibit uncontrolled
proliferation.p53 appears to control acritical cell cycle checkpoint
reponsible for maintaining genomic integrity by inducing growth
arrest and subsequent DNA repair inGI ofthe cell cycle following
sublethal DNA damage (Kastan et al, 1991). p53 functions
biochemically as a sequence-specific DNA-binding transcription
factor (Zambetti et al, 1992; Cho et al, 1994) and induces down-
stream genes resulting in cellulardeath in some cell types (Yonish-
Rouach et al, 1991; Shaw et al, 1992; Lane, 1993). Homozygous
alterations in p53, resulting in a non-functional protein, are the
most frequently identified genetic aberrations identified in solid
tumours (Greenblatt et al, 1994); but this appears not to be true for
NB (Davidoff et al, 1992; Imamura et al, 1993; Vogan et al, 1993;
Hosoi et al, 1994). The accumulation of p53 in neoplastic cells
appears to be critically dependent upon influences from the
cellular environment (Voijtesek and Lane, 1993; Lane, 1994),
apart from simply reflecting the protein's intrinsic structure and
stability (Hall and Lane, 1994).
The retinoblastoma (Rb) tumour-suppressor gene product
restricts cell cycle progression at G,/S by virtue of its ability to
inhibit transcription factors, and may also play a role in apoptosis
inhibition, as proteins that inhibit Rb function also induce apop-
tosis. (Rao etal, 1992; White et al, 1994; White, 1994; Haas-Kogan
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Table Relation of clinical and histological parameters to immunocytochemical and TUNEL results obtained in clinical tumours
Patient Outcomea Stageb Age at Tx Pre- Gender Tumor N- F/U Grade9 Lobule Bcl-2 PCNA Rb p53 Bax TUNE
number diagnosis biopsy?' locationd myce (months)' patternh (%) (%) (%) (%) (%) (%)
1 NED 1 2 months N F Para-renal 1 64 PDI + 60 11 10 0.5 7 6.5
2 NED 1 2 months N M Para-renal 1 46 PDL + 80 1.6 34 12 2 0.4
3 NED 1 Birth N F Para-renal 1 39 PDH + 60 11 1 0.4 4 4.7
4 NED 1 1 month N M Pelvic 1 56 PDH - 60 7 5 5 1 0.4
5 NED 1 Birth N F Adrenal 1 61 PDL + 80 9.0 12 1 0 2.3
6 NED 2a 6 months N F Cervical 1 25 PDI + 60 7.5 10 2 6 0.5
7 NED 2a 18 months N F Thoracic 1 65 PDI - 90 11 22 0.3 0.8 1.2
8 NED 2b 3 months N F Thoracic 1 94 PDH + 50 16 30 8 0 1.0
9 NED 2b 2.5 years N M Pelvic 1 41 PDL + 30 11 1 12 5 0.7
10 NED 3 1 month N F Thoracic 1 64 PDH 30 8.8 10 30 0.2 1.0
11 NED 3 7 months N M Pelvic 1 48 PDH + 40 6.5 3 6 1 1.3
12 NED 3 12 months Y F Para-adrenal 1 34 PDL + 30 1 5 0.1 1 1.2
13 NED 3 1 year Y F Thoracic 1 39 PDI - 60 0.5 2 3 6 0.4
14 NED 3 13 months N F Para-adrenal 1 75 PDI + 50 13 30 4 3 1.6
15 NED 4 10months N F Adrenal 6-8 59 PUH - 15 25 18 2 1 1.4
16 NED 4 11 months Y M Adrenal 1 57 PUI - 5 40 27 5 0.7 3.4
17 NED 4 3.5 years Y F Abdominal 1 61 PDI + 35 14 10 5 0 6.9
18 NED 4S Birth N M Adrenal 1 65 PDL + 30 2.8 40 3 0 0.2
19 NED 4S 5 months N M Subcutaneous 1 20 PUL - 30 18 5 1 0 0.1
20 DODi 3 Birth N M Para-renal 6 0 PDL + 30 17 2 7 0.3 1.3
21 DOD 3 2 years Y F Adrenal 1 2 PUH - 30 9.3 1 20 0 0.8
22 DOD 3 3 years Y M Adrenal 70 16 PUH - 13 2.2 8 25 0.2 0.1
23 DOD 3 5 years Y M Thoracic 1 17 PUH - 50 0.6 12 28 0.4 0.7
24 DOD 4 10 months N M Adrenal 70 14 PUH - 3 20 10 10 1 0.3
25 DOD 4 10 months Y F Adrenal 40 5 PDH - 10 13 7 0.4 0.1 0.4
26 DOD 4 4.5 years Y F Adrenal 40 27 PUH - 10 69 5 0.5 0.5 1.5
27 DOD 4 4.5 years Y M Adrenal 40 8 PUI - 15 88 7 22 0.1 0.2
28 DOD 4 6 years Y M Adrenal 1 12 PUH - 3 70 22 40 1 0.2
29 DOD 4 6.5 years Y F Thoracic 1 8 PUH - 30 12 3 17 0.4 0.3
30 DOD 4 7 years Y M Adrenal 1 16 PUH - 10 3.7 8 51 0.5 0.3
31 DOD 4 11.5 years Y M Adrenal 40 8 PUH - 15 77 14 39 1 0.4
32 DOD 4S Birth N M Adrenal 1 2 PDL - 30 2.8 8 3 0 0.2
33 DODi 4S Birth N F Adrenal 1 1 PDI + 80 33 50 5 1 0.3
34 NED GNB3 3.5 years N M Thoracic 1 91 RWD - 10 29 12 0.4 30 0.1
35 NED GNB3 3.5 years N M Thoracic 1 83 RWD - 4 18 25 2 25 0.1
36 NED GN 5 years N M Pelvic 1 40 RWD - 10 0.1 10 7 57 0.2
37 NED GN 2.5 years N F Thoracic 1 76 RWD - 10 2 22 1 70 1
38 NED GN 4.5 years N M Pelvic 1 46 RWD - 15 25 27 0.5 80 0.1
aOutcome: NED, no evidence of disease; DOD, dead of progressive disease. bClinical stage at time of diagnosis by INSS criteria; GN, ganglioneuroma; GNB,
ganglioneuroblastoma. cTx pre-biopsy? indicates whether chemotherapy was initiated before biopsy (Y), or not before biopsy (N). dPrimary location refers to
gross and histopathological site of primary tumour. ON-myc refers to gene copies per haploid genome; data reproduced from Hedborg et al (1995b). 'Follow-up
(F/U) indicates time period from diagnosis to most recent enquiry or time of death.9By Shimada's classification criteria: degree of stroma development; R,
stroma-rich; P, stroma-poor. Differentiation grade by Shimada's classification criteria; U, undifferentiated histology; D, differentiating histology; Int, intermediate;
WD, well differentiated. Nuclear morphology, mitosis-karyorrhexis index (MKI); L, low; I, intermediate; H, high; data summarized from Gestblom et al, 1995.
hPresence (+) or absence (-) of lobular architecture pattern of differentiation, as described. Death in two patients not directly a cause of advancing tumour
progression; death in isecondary to neuroendocrine crisis, and isecondary to tumour mass-induced respiratory compromise. Immunocytochemistry and TUNEL
results indicate the percentage of tumour chief cells in each tumour in which respective positive staining was apparent.
et al, 1995). Relationships between Rb and p53 in cell cycle regula- Functional interactions between the p53 and the gene products
tion may be suggested based on the action of other proteins regu- of the bcl-2 gene family may also exist (Cory et al, 1994). The
latedbyp53. p21 (also referred to asCipi, WAFI and Sdil), which bcl-2 gene product is recognized to maintain or prolong cellular
is transcriptionally induced by p53, thereafter inactivates other survival in a variety of situations (Garcia et al, 1992; Altsopp et al,
factors required for cell cycle progression (Harper et al, 1993). In 1993; Reed, 1994), furtherevidence indicated by the extensive and
the absence of p21, these other factors complex with cyclins to inappropriate apoptotic cell death in homozygous genetic deletion
phosphorylate Rb, the under-phosphorylated form exerting a nega- animals (Veis et al, 1993). A number of Bcl-2 complexing homo-
tive regulatory effect on gene expression by complex formation logues, including Bax, have also been identified. While Bcl-2
with other DNA-binding proteins (Buchkovich et al, 1989; Chen et homodimers promote cell survival, progressive concentration-
al, 1989). Thus, Rb may function by sequestering other cellular dependent transition to Bax homodimers has been suggested to
proteins with growth-promoting activities. Both Rb and p53 are promote cell death (Oltval et al, 1993). p53 may regulate the rela-
involved in cell cycle regulation, Rb apparently being essential for tive stoichiometry of these proteins by inducing decreases in
exit from the cell cycle, whereas p53 activation can inhibit cell Bcl-2 and increases in Bax (Miyashita et al, 1994; Selvakumaran
cycle progression (Cordon-Cardo, 1995). et al, 1994).
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In this investigation, we examine the cellular expression ofthese
cell cycle checkpoint genes in a well-documented group ofclinical
NB tumours. We concurrently examine cellular proliferation,
differentiation and apoptosis in relation to the expression of these
gene products. The spatial organization of the expression patterns
obtained will be discussed in relation to tumour architecture.
MATERIALS AND METHODS
Tumour materials
A total of38 infants andchildren with NB, ganglioneuroma (GN) or
ganglioneuroblastoma (GNB) were identified from a population-
based, consecutive inquiry of all medical centres in Sweden that
provide surgical treatment of the disease. Adequate clinical data,
follow-up and sufficient histological materials were criteria for
study inclusion. Biopsy or resection specimens of primary, and in
some instances metastatic, tumours were evaluated. Tumour stage
was determined clinically at the time ofsurgical biopsy orresection
in accordance with INSS criteria (Brodeur et al, 1993). Patients
were at varying stages oftreatment at the time oftissue acquisition;
the majority of patients with stage 3 and 4 disease received cyto-
toxic therapy before the time of tumor biopsy or resection (60%),
whereas those with stage 1, 2, 4S, GN orGNB had not (0%). Patient
characteristics are summarized inTable 1. At a median follow-up of
56 months, all nine patients with Stage 1, stage 2a and 2b disease
are alive and free of disease. Ofchildren with stage 3 disease, four
out of nine (44%) have died, whereas 8/11 (73%) of children with
stage 4 tumours have succumbed to progressive disease. N-myc
amplification of greater than tenfold was associated with 100%
mortality (6/6). All tumours were histologically graded with respect
to stroma content, extent of differentiation and mitosis-karyor-
rhexis index, in accordance with previously reported criteria
(Shimada et al, 1984). Statistical comparisons of outcome with
other prognostic features in this group of patients have previously
been reported (Hedborg et al, 1995b).
Tissue preparation and immunohistochemistry
Tumour samples were fixed in 4% buffered formaldehyde,
embedded in paraffin and sections of4-5 ,um were secured to glass
pretreated with silane and acetone. Deparaffinization was performed
by baking slides ovemight at 370C, and transfer through xylene and
progressive dilutions ofethanol to deionized distilled water (DDW).
Deparaffinized tissue sections were subjected to microwave
treatment in 10 mm sodium citrate buffer, pH 7.3, for 15 min at
750 W. Tissue sections were washed in DDW and blocked with
2% bovine serum albumin (BSA) in Tris-HCl buffered saline
buffer for 20 min. Primary antibody at optimal dilution was added
to sections with incubation from 1 h to overnight at either room
temperature (RT) or 4°C respectively. Slides were rinsed and then
incubated for 30 min at RT with either appropriate alkaline phos-
phatase-conjugated or biotin-conjugated secondary antibody at
1:40 dilution (Sigma Chemical Co., St Louis, MO, USA). Sections
were again rinsed and developed using Fast-red-TR-salt or 3-
amino-9-ethylcarbazole (both Sigma) as chromogen. Slides were
rinsed in tap water, some sections counterstained with haema-
toxylin, and mounted. Negative controls were obtained by exclu-
sion of primary or secondary antisera, and primary antiserum
replacement with species-appropriate non-immune antisera
(Sigma) at equivalent concentrations.
The primary antibodies used in this study and their documented
characterization and/or previous employment are as follows: mono-
clonal anti-Bcl-2 antibody (MAB 124; Dakopatts, Glostrup,
Denmark) (Pezzella et al, 1990; Hockenbery et al, 1991) at 1:100
dilution, monoclonal anti-neuron-specific enolase (NSE) antibody
(Dako-NSE, H14; Dakopatts) (Hoehner et al, 1995a) at 1:50 dilu-
tion, monoclonal anti-tyrosine hydroxylase (TH) antibody (Rohreret
al, 1986; Hoehneretal, 1995a) (BoehringerMannheim, Germany) at
1:75 dilution, monoclonal anti-PCNA antibody (Kurki et al, 1988;
Hall et al, 1990; Gestblom et al, 1995) (Boehringer Mannheim) at
1:50 dilution, monoclonal anti-p53 antibody (DO-7; Dakopatts)
(Jacquemier et al, 1994; Nylander et al, 1995) at 1:200 dilution,
monoclonal anti-p53 antibody (Ab-2; Oncogene Science,
Uniondale, NY, USA) (Jacquemier et al, 1994) at 1:100 dilution,
monoclonal anti-Wafl (p2l) antibody (clone EAlO; Oncogene
Science and a gift from B Vogelstein) at 1:50 dilution, polyclonal
anti-Bax antiserum (N-20; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) at 1:50 dilution, and polyclonal anti-Rb antiserum (Santa
Cruz Biotechnology) at 1:100 dilution.
DNA nick end-labelling of tissue sections
A procedure specifically to end label DNA cleavage sites in tissue
sections in situ (TUNEL) was employed as previously described
with minor modifications (Gavrieli et al, 1992; Hoehner et al,
1995b). Tumour sections were deparaffinized and incubated in a
moist chamber for 15 min with 20 jig ml-1 proteinase K (Sigma).
Hydrogen peroxide (2%) was added for 5 min to inactivate
endogenous peroxidase, followed by incubation at 370C for
60 min with terminal deoxynucleotidyl transferase (10 eu 50 l-1)
and biotinylated deoxyuridine (dUTP; 0.5 nmol 50 j1-1) (both
Boehringer Mannheim) in transferase buffer (30 mm Tris-HCl
buffer of pH 7.2, 140 mm sodium cacodylate and 1 mm cobalt
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Figure 1 Quantitative immunocytochemical and TUNEL reactivities in NB
tumours. Calculated immunocytochemical or TUNEL reactivity density in NB
tumours; bars represent the mean percentage of tumour cells staining
positively for each analysis (ordinate), stratified according to outcome;
survivors (O), n = 19; non-survivors (E), n = 13. Error bars represent
standard error of the mean. *Indicates statistically significant differences
comparing survivors and non-survivors (P< 0.05, Student's t-test)
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tumourUwith lobular features, processed for TH (A and B), NSE (C), Bc1-2(D),combinedPCNA/TUNEL (E), p53 (F) and p21 (G); and a ganglioneuroma
MW.~ %-e -,osa
processed for Bax (H). Low-power photomicrograph in (A) depicts a typical lobular arrangement of tumour cells bounded peripherally by fibrovascular tumour
stroma (*) and possessing a central cellular-poor zone. Higher power magnification in (B) indicates TH non-reactivity in cellular dense, cytoplasmic-poor, poorly
differentiated tumour cells adjacent to fibrovascular tumour stroma (*), and intense red immunoreactivity in more centralized tumour cells (black arrows). Similar
results obtained with NSE antiserum (C), clearly identifying more differentiated centralized tumour cells by their more abundant NSE reactive cytoplasm (black
arrows), and their larger, less dense nuclei. In contrast, Bc1-2 immunoreactivity (D) is most apparent in immature tumour cells adjacent to fibrovascular stroma
(*), and absent in more differentiated cells (arrows). (E) Combined PCNA (blue) and TUNEL (brown) processing confirms proliferation is most apparent in less-
mature tumour cells (black arrow), whereas TUNEL positivity (white arrow) is most evident in cells with condensed nuclei, lying far displaced from fibrovascular
stroma. Brown p53 immunoreactivity (F) confined to differentiated and centralized tumour cells abutting region rich with apoptosis. Brown p21 positivity (G)
scattered but evident in groups of cells similar to those possessing p53 reactivity. (H) Bax immunoreactivity in mature ganglion cells of ganglioneuroma tumour.
Counterstaining with haematoxylin in all instances except (E). White arrows in (C-G) designate cells with nuclear morphology suggestive of apoptosis. Scale
bars: A, 200 jim; B, E, F, G and H, 80 jm; C and D, 50 gm
British Journal ofCancer (1997) 75(8), 1185-1194 0 Cancer Research Campaign 1997Apoptosis-relatedgene expression in NB 1189
chloride). Reaction was terminated by immersion in. 300 mM
sodiumchloride, 30 mm sodium citrate buffer for 15 min, and then
incubated with AB complex (1:100 avidin and 1:100 biotinylated
horseradish peroxidase in 0.1% BSA) (Dakopatts) for 30 min
according to the manufacturer's instructions. Sections were
immersed in phosphate-buffered saline (PBS) for 5 min, devel-
oped in 3-amino-9-ethylcarbazole solution for 20 min at RT,
washed in DDW and mounted.
Combined immunocytochemistry and TUNEL
Tumour sections were sequentially processed for anti-PCNA
immunocytochemistry using BCIP/NBT (Sigma) as chromogen,
and thereafter with TUNEL as described above (Gestblom et al,
1995). Procedure modification included only the omission of
proteinase K treatment. Counterstaining was notperformed.
Result quantitation
All tumours were processed and analysed blind coded without
knowledge of tumour stage, outcome or patient identity. The
average numberoftumourcells proper perhigh-powerfield infive
randomly selected regions of each specimen was determined, and
the total number of immunoreactive or TUNEL-positive cells in
each of these five fields was similarly determined. A density
percentage ofpositive cells was calculated fromthese fiveregions,
and the mean determined foreach tumour, asdepicted in theTable.
Cellular positivity was counted if chromogenic reactivity was
considerably greater than background. Tumour regions with
apparent necrosis were avoided. Consistent results were obtained
between repeat experiments and between different block sections
of tumour tissue from the same patient. Standardized specimens
were analysed with each assay to ensure reproducibility of the
density scoring scale. The immunocytochemical positivity density
mean and standard error for NB tumours stratified according to
outcome was calculated, and statistical comparison performed
using the Student's t-test (Figure 1). Stratification and statistical
comparisons were alsoperformedusing the presence or absence of
cytotoxic therapy before tissue acquisition as criteria; however,
comparisons between these two groups foreachitem studiedfailed
to reveal any statistically significant differences. Statistical signif-
icance was considered achieved with a P-value less than 0.05.
Although portions ofthis work have, in part, been reported previ-
ously, i.e. results concerningTUNEL, Bcl-2 and PCNA (Gestblom
et al, 1995; Hoehner et al, 1995a, b), all data concerning p53, Rb,
Bax and p21 have not been reported previously.
RESULTS
Characterization of neuroblastoma tumours
All tumours were classifiedhistologically and tumourcell differen-
tiation evaluated using morphology in conjunction with TH and
NSE immunoreactivity, both markers ofsympathetic neuronal and
neuroendocrine differentiation. Stroma-poor tumours classified as
histologically undifferentiated (Shimada et al, 1984) lack a well-
developed supportive fibrovascular stroma, as well as criteria
representative of more advanced morphological differentiation
(Table). In these tumours, TH and NSE were expressed in a
random, scattered pattern(data not shown), clearly consistent with
theirpresumed SNS origin. In contrast, stroma-poor NB specimens
possessing differentiating histological characteristics displayed a
disparate pattern of TH and NSE immunocytochemical reactivity
(Figure 2A-C). Differentiated tumour cells, identified by their low
nuclear to cytoplasmic ratio andpale haematoxylin-staining nuclei,
displayed intense cytoplasmic TH and NSE immunoreactivity
compared with tumour cells with immature morphology, identified
by their dense haematoxylin-stained nuclei and scant cytoplasm.
We have previously reported the existence of 'tumour lobule'
architecture in selected differentiating histology tumours (Hedborg
et al, 1995a; Hoehner et al, 1995a), an arrangement by which a
continuum of neuroendocrine tumour cell differentiation can be
more easily identified (Figure 1). In these tumours, TH immunore-
activity was least evident in tumour cells adjacent to the thin
fibrovascular stroma (Figure 2A and B), these tumour cells typi-
callypossessing dense nuclei and scantcytoplasm, reflecting lesser
cellular differentiation. TH expression progressively increased in
morphologically more differentiated tumour cells nearing the
centre of the lobule structure. Findings with NSE were similar,
intense positivity clearly identifying tumourcells with more differ-
entiated morphological characteristics identified by their abundant
cytoplasm (Figure 2C). Of the 14 tumours with this 'tumour
lobule' arrangement ofcells, all show differentiating histology, all
but one were discovered in patients less than 13 months ofage, and
12/14 enjoyed favourable outcome at extended follow-up (Table).
Of the two non-survivors, one death was the result of haemody-
namic neuroendocrine crisis rather than tumour progression, and
the otherpatient with neonatal 4S disease succumbed secondary to
massive tumour volume causing severe respiratory distress.
Proliferating cell (PCNA) immunocytochemistry
Proliferating cell nuclear antigen (PCNA) immunoreactivity was
exclusively nuclear, positive cells often displaying morphological
evidence of mitotic activity, but more often morphologically non-
mitotic in appearance. Positive controls, including the basal
germinal layer of the epidermus, basal intestinal epithelial crypt
cells and fetal adrenal cortex, confirmed PCNA positivity in those
tissues known to have high proliferative rates (not shown). In NB
tumours, the cellular density ofPCNA-positive tumourcells corre-
lated with unfavourable patient outcome (Figure 1) (Gestblom et
al, 1995). The majority of undifferentiated tumours displayed
PCNA positivity in a randomly scattered pattern; however, in
differentiating tumours with lobule architecture, the greatest
density of reactive tumour cells was located adjacent to thin
fibrovascular stroma and capillaries (Figure 2E). In tumour
regions more distant from this vascular supply, PCNA-positive
cells became less frequent.
Apoptosis-related gene expression
Nuclear-specific p21 immunoreactivity was identified in all
tumours examined; however, p21-reactive cells were scattered and
sparse, with a cellular density never exceeding 5% of the total
tumour cell number (not shown). p21 was exclusively localized to
tumour cells, immunoreactivity detected in cells displaying both
morphologically mature and immature differentiation characteris-
tics, and was not identified in adjacent normal tissues or fibro-
vascular tumour stroma. In undifferentiated tumours, p21-
positive tumour cells were always sparse and randomly scattered.
In differentiating tumours, localized collections of morphologi-
cally differentiated p21-positive cells were occasionally observed,
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Figure 3 In situ apoptosis-related gene expression, proliferation,
differentiation and cell death in differentiating 'lobular' NB tumours. Graphic
demonstration of results described in text. In tumours with lobular
architecture, seemingly physiological apoptosis-related gene expression
exists as tumour cells gain increasing distance from fibrovascular tumour
stroma, develop increased morphological and biochemical neuroendocrine
differentiation, and subsequently develop a morphological appearance
suggestive of apoptosis. High proliferation rate in tumour cells adjacent to
and restricted by fibrovascular stroma postulated to displace more
centralized cells towards the lobule centre (right). Expression of apoptosis-
related genes and the proliferation marker PCNA, as well as detection of
DNA fragmentation (TUNEL) in different regions of the tumour 'lobule' are
also represented: (-) cellular reactivity not detected; (+/-) positive cells
occasionally detected in a non-confluent pattern; and (+) confluent clusters of
positive cells identified
interspersed with other morphologically highly differentiated
tumour cells (Figure 2G).
Bcl-2 immunoreactivity was identified in all tumours examined.
Reactivity was exclusively cytoplasmic, and positive controls,
including lymphocyte aggregates, sympathetic ganglia and
intestinal epithelia, were in accordance with previously reported
immunoreactivity results (Hockenbery et al, 1991; LeBrun et al,
1993; Lu et al, 1993; Hoehner et al, 1995a). Positivity was local-
ized to tumour cells proper and absent from cells comprising the
fibrovascular tumour stroma. In differentiating tumours, the
morphologically most differentiated tumour cells were frequently
Bcl-2 non-reactive, whereas morphologically immature or inter-
mediately differentiated tumour cells possessed Bcl-2 positivity
(Figure 2D). The majority of cells in the homogeneous and
morphologically immature tumour cells of undifferentiated
tumours were typically Bcl-2 negative, as reflected by the signifi-
cantly lower density ofcellular positivity (Figure 1).
Rb immunoreactivity, specifically localized to the nucleus, was
identified in a large proportion oftumour cells, approximating the
pattern of immunoreactivity observed with PCNA immunocyto-
chemistry. Adjacent normal fibroblasts and endothelial cells,
among others, also displayed nuclear Rb immunoreactivity. In
particular, tumour cells with intermediate morphological differen-
tiation characteristics were most often Rb immunoreactive. The
morphologically most differentiated tumourcells wereparticularly
non-reactive. The tumour cellular density of Rb reactivity, as
demonstrated in Figure 1, failed to confirm statistical correlations
with outcome.
Tumour cell p53 immunoreactivity was observed in all NB
tumours examined. Reactivity was nuclear restricted, and neither
cytoplasmic p53 immunoreactivity nornon-neoplastic cellularposi-
tivity was appreciated. Both anti-p53 antiseraused in this investiga-
tion gaveequivalent andconsistent results. The majority oftumours
exhibited scatteredp53 cellular staining, ranging from a very sparse
cellular density positivity to 80% of cells displaying immuno-
cytochemically detectable p53 protein (Table). Comparisons ofthe
density ofp53-positive tumour cells (antiserum DO-7) with patient
outcome confirms the significantly higher density of p53-positive
tumour cells in tumours from patients with unfavourable outcome
vs long-term survivors (Figure 1), in accordance with previous
reports (Davidoff et al, 1992). Furthermore, in tumours which
exhibit evidence of heterogeneous morphological tumour cell
differentiation and lobule architecture, p53 protein was most
frequently detected in the most differentiated cells located distant
from tumour fibrovascular stroma, and immediately adjacent to
tumour cells with morphological characteristics of apoptosis
(Figure 2F). p53 was typically absent from tumour cells lying close
to the fibrovascular tumour stroma with morphologically less-
differentiated characteristics.
Bax immunoreactivity was not detectable in a number ofthe NB
tumours studied. Only large differentiated cells ofGN tumours and
the most differentiated cells of some differentiating NB tumours,
often arranged in pseudorosettes, revealed Bax immunoreactivity
(Figure 2H). Immunoreactivity was restricted to the cytoplasm of
these cells. Bax immunoreactivity was particularly absent in
tumours lacking evidence of morphological differentiation.
Positivity was confirmed in differentiated neurons of dorsal root
ganglia, spinal cord and sympathetic ganglia of normal human
fetal and post-natal specimens, in accordance with previous reports
(Krajewski et al, 1994; Miyashita et al, 1994) (not shown).
Apoptosis detection
TUNEL staining, which identifies DNA fragmentation in situ, was
identified in all tumours examined, the cellular density ofwhich is
depicted in the Table. Statistical correlations confirm the previ-
ously reported relation between TUNEL positivity and favourable
patient outcome (Figure 1) (Gestblom et al, 1995; Hoehner et al,
1995a). Positivity was exclusively nuclear, the morphology of
positive cells often suggestive of apoptosis, with condensed,
pyknotic and often fragmented nuclei. TUNEL-positive cells were
often randomly scattered in tumours, but were also occasionally
identified in groups. In differentiating tumours, TUNEL-positive
cells were most abundant in tumour regions distant from the
fibrovascular stroma bordering the morphologically most differen-
tiated tumour cells (Figure 2E).
DISCUSSION
Architectural arrangement of solid tumour growth
The spatial arrangement ofangiogenesis, tumour cell proliferation
and cellular death in other solid tumour models sheds light upon
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the molecular events that we report. Solid tumourgrowth is highly
dependent upon vascular acquisition (Folkman, 1990). Tumours
grown in isolated perfused organs in which vessels fail to prolif-
erate are limited to 1-2 mm3 in size (Folkman et al, 1966), as are
tumours that remain viable but avascular under experimental
conditions in vivo (Gimbrone etal, 1974). With induction ofangio-
genesis and vascularincorporation, tumourgrowth occurspredom-
inantly along these newly formed vessels, the density of which is
higher at the tumour periphery than at the centre (Thompson et al,
1987). Tumour cell proliferation also diminishes with increasing
distance from the nearest capillary (Tannock, 1970). The topog-
raphy and mode of cellular death in tumours is determined largely
by the rate of tumour cell proliferation relative to the process of
angiogenesis, but is alsocritically dependent upon intrinsic tumour
cell properties (Arends et al, 1994). Locally expanding tumours
may produce hypoxia-induced necrotic zones, observed at a strik-
ingly constant distance from blood vessels both in vitro and in vivo
(Tannock, 1968; Franko and Sutherland, 1979). However, cell lines
withhigh in vitro apoptotic rates generate slowly growing tumours
withhigh ratios ofapoptosis to mitosis and little necrosis; but lines
with low in vitro apoptotic rates generate rapidly expanding
tumours with high mitotic rates, extensive necrosis and little apop-
tosis relative to mitosis (Arends etal, 1994). Compromisedregions
in either system display regions ofapoptosis adjacent to necrosis.
Histological arrangement of lobular architecture NB
tumours
Fourteen differentiating 'lobular' NB tumours, which additionally
possess clinically favourable characteristics, displayed similar
spatial organization (Figure 3). The three-dimensional architecture
of an individual tumour lobule is spheroidal, limited circumferen-
tially by fibrovascular stroma, and often possessing a central cell-
poor zone. Morphologically immature tumour cells located
immediately within this thin fibrovascular stromal shell often
express Bcl-2 and are proliferating, as evidenced by Ki-67
(Hedborg et al, 1995a) and PCNA positivity. In this study, we
report that as tumour cells gain an increasingly more centralized
distance from the fibrovascular stroma, cells not only develop
increasing evidence ofmorphological and biochemical differentia-
tion, but develop Rb immunoreactivity, lose Bcl-2 immunoreac-
tivity and cease proliferating. The arrangement of proliferating
cells immediately bounded by a limiting framework suggests that
adjacent but more centralized cells are progressively displaced
further from the fibrovascular tumour stroma towards the lobule
centre. Still more centralized, morphologically and biochemically
highly differentiated tumour cells, which often express p53 and
occasionally p21 and Bax, lie adjacent to another morphologically
distinct group of tumour cells that not only lack Bcl-2 expression,
but are TUNEL positive. These TUNEL-positive cells possess
scant cytoplasm and pyknotic, condensed nuclei, thus meeting
established criteria for apoptotic cellular death (Kerr et al, 1972;
Wyllie et al, 1980). They often lie clustered a strikingly constant
distance from their nearest vascular support, typically 150-
300 gm, occasionally bordering neuropil, necrosis and/or calcifi-
cations (not shown).
Organization of undifferentiated NB tumours
All NB tumours in this investigation that proved fatal as a result of
tumour progression failed to possess the tumour lobule character-
istics described above. Patterns of immunoreactivity and TUNEL
positivity in these tumours were randomly scattered, and neither
consistent morphological tumour cell differentiation nor a well-
developed/organized fibrovascular stroma was readily appreci-
ated. Although quantitative findings indicate that unfavourable
outcome tumours possess a lower proportion of Bcl-2-positive
tumourcells, this varies among reports (Castle et al, 1993; Ramani
and Lu, 1994; Hoehner et al, 1995a; Ikegaki et al, 1995; Krajewski
et al, 1995). Undifferentiated and/or unfavourable outcome NB
tumours often accumulate p53 protein; results in agreement with
others (Davidoffet al, 1992; Moll et al, 1995). Fatally progressive
tumours also possess a higher rate of proliferation and a lower
percentage of apoptotic cells, consistent with other reports
(Gestblom et al, 1995; Hoehner et al, 1995a) and with results
obtained in defined solid tumour systems (Arends et al, 1994). The
finding that Rb is quantitively homogeneous among clinical NB
tumours is in keeping with the findings that Rb protein expression
is relatively high in a number ofNB cell lines (Ikegaki et al, 1991,
1994) and exists in normal maturing tissues, both proliferating and
non-proliferating (Cordon-Cardo and Richon, 1994).
In situ association oftumourarchitecture, proliferation,
cellulardeath andapoptosis-relatedgene expression
To explain these prognostic, cellular architectural and cellular gene
expression findings, we conclude that at least two principally
disparate forms of NB tumours exist. One form in which genetic
aberrations cause severe disruption in the normal control of cell
cycle checkpoint gene regulation and differentiation, i.e. prognosti-
cally unfavourable tumours; and a second form in which the genetic
impetus for the malignant phenotype does not severely impede
these processess and molecular events proceed as expected in lieu
of the tumour architectural limitations. From a genetic, biological,
histological and clinical sense, this view ofdistinctly disparate NB
tumour types has factual support (Brodeur, 1995; Hedborg et al,
1995b). One tumour form frequently harbours amplification ofthe
N-myc gene, has undifferentiated histology, is diffuse and/or
metastatic, occurs in older children, and is most often fatally
progressive; and another form possesses a normal N-myc copy
number, differentiating histology, localized growth, and is discov-
ered in younger children who typically survive their disease.
In biologically and clinically unfavourable tumours, tumour
organization is typically poorly structured. Although this creates
difficulties in spatially defining cell cycle regulatory gene expres-
sion patterns, quantitative findings suggestthatinappropriate regu-
lation exists, i.e. elevated p53 and low Bcl-2, with high
proliferation. In contrast, many NB tumours with favourable prog-
nostic features appear to possess relatively physiological expres-
sion ofthese genes (Figure 3). In these tumours, Bcl 2 is intensely
expressed by those immature tumour cells that lie adjacent to the
fibrovascular stroma, and is down-regulated as proliferation
causes more centralized displacement of these tumour cells. As
cellular differentiation occurs, tumour cells die by apoptosis at a
relatively constant distance from the nearest vascular supply.
Down-regulation of Bcl-2 in this situation would be predicted not
only by similar findings in fetal sympathetic
nervous system cells that choose an adrenal or extra-adrenal chro-
maffin differentiation lineage (Hoehner et al, 1995a; Krajewski et
al, 1995), but also by cells whose death is defined as apoptotic
(Hockenbery et al, 1991; Greenlund et al, 1995). Although Bcl-2 is
best characterized as a gene that protects against cell death,
another view is that these Bcl-2-positive tumours are 'primed' or
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possess the machinery required for cellular suicide, as supported
by others (Hockenbery et al, 1991). Bax expression was detected
solely in the most mature cells of differentiating NB and GN,
although low-level expression cannot be excluded. This finding
fits well with previous reports documenting Bax localization to
normal sympathetic neurons (Krajewski et al, 1994; Miyashita et
al, 1994); however, expression patterns, which would help verify
that Bax counteracts the survival effects of Bcl-2 (Oltval et al,
1993) andthus potentiates apoptosis, were notfrequently observed
even in NB tumours characterized by more extensive apoptotic
cell death. The finding that clusters of p53-positive cells lie just
adjacent to tumour regions rich with apoptosis fits well with its
determined function. p53 is normally up-regulatedby toxic agents,
UV irradiation orhypoxia, this believed to allow time forenacting
DNA repair (Maltzman and Czyzyk, 1984; Hall et al, 1993; Lu
and Lane, 1993). Although clinical tumour studies have confirmed
genetic point mutations as a frequent cause of p53 accumulation
(Greenblatt et al, 1994), environmental conditions may also influ-
ence protein stability or gene transcription and therefore alter the
cellular content ofp53 protein (Lane, 1993; Hall and Lane, 1994).
In 'lobular' NB tumours, p53 is specifically localized to tumour
cells that lie some 15-25 cell diameters from their most immediate
blood supply. At this location, tumour cells no longer proliferate,
they have lost or down-regulated their survival gene bcl-2, and
they up-regulate the expression of p53, presumably to attempt
damage repair in a region compromised of blood-borne metabo-
lites. Ifthis is unsuccessful, apoptosis would occur. Therefore, p53
regulation in these tumours might be physiological, and is acti-
vated/expressed in those cells in which cellular insults have
occurred as they acquire distance from their metabolic vascular
supply. Although cellular expression ofp21 was typically sparsely
scattered in these tumours, p21 was occasionally localized to the
same group of tumour cells that harboured p53 positivity. As p21
is known to function downstream of p53 (el-Deiry et al, 1993),
cellular co-expression of these two molecules may represent acti-
vation of a common pathway directed towards cellular repair
and/or apoptosis. Rb protein was localized to maturing cells either
proliferating or non-proliferating in accordance with other reports
(Cordon-Cardo and Richon, 1994). It appears to be absent from
the most differentiated tumour cells, as well as from those cells
actively undergoing apoptosis.
Implications
A subset of clinical NB tumours has been identified in which cell
cycle checkpoint and apoptosis-related gene expression appear
spatially and potentially physiologically linked in situ (Figure 3).
The arrangement of cells in these tumours reflects ongoing angio-
genesis, proliferation, necrosis and apoptosis, in part analogous to
the spatial relationships described in other experimental tumour
systems. Therefore, NB may represent a particularly relevant
system, both clinically and physiologically, for examining the
normal in vivo regulation of these genes. Interestingly, this cellular
organization is identified primarily in a subset of tumours with
favourable biological characteristics, tumours that may also possess
regressive tendencies. Althoughblood-borne oxygen, metabolites or
growth factors, such as neurotrophins (Hoehner et al, 1995b), could
be involved in directing the observed molecular and histological
events, other microenvironmental, endothelial/stromal-derived or
adjacent tumour cell paracrine interactions could also be indicated.
An interesting observation is that concurrent with this molecular
cascade ofevents,morphological differentiation oftumourcells also
occurs. Nonetheless, this architectural arrangement suggests that
exogenous ordiffusable factors may possess significantcontrol over
tumour growth, cellular differentiation and programmed cell death
in some tumours, whereas other tumours may be relatively refrac-
tory to these influences, possibly a reflection of their intrinsic
genetic mutations.
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